Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes

J Endocrinol Invest. 2024 May;47(5):1047-1049. doi: 10.1007/s40618-023-02290-2. Epub 2023 Dec 29.

Authors

A Basolo¹, P Fierabracci², G Salvetti², F Santini²

Affiliations

¹ Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, 56124, Pisa, Italy. [email protected].
² Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, 56124, Pisa, Italy.

PMID: 38157134
DOI: 10.1007/s40618-023-02290-2

No abstract available

Keywords: Cardiovascular outcomes; Obesity; Semaglutide.

Publication types

Letter

MeSH terms

Cardiovascular Diseases* / etiology
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy
Glucagon-Like Peptides* / therapeutic use
Humans
Hypoglycemic Agents / therapeutic use
Obesity* / complications
Obesity* / drug therapy

Substances

semaglutide
Glucagon-Like Peptides
Hypoglycemic Agents